Interestingly, it had been shown earlier that in an MSH2-deficient mouse model developing CRC, FOLFOX treatment led to a reduction in tumor volume, and MMR status was found not to modify responsiveness to oxaliplatin in previous studies [81,82]. The gene discussed is MSH2; the disease is colorectal carcinoma.